Introduction
============

Head and neck cancer (HNC) comprises a set of cancers that affect the oral cavity, pharynx and larynx ([@b1-mmr-17-02-2982]), with \~600,000 newly diagnosed cases and \~300,000 mortalities annually ([@b2-mmr-17-02-2982]). Oral squamous cell carcinoma (OSCC) is the most common malignant tumor of the HNCs and the sixth most common cancer worldwide, and accounts for \~90% of all the oral cancers ([@b3-mmr-17-02-2982],[@b4-mmr-17-02-2982]). OSCC early detection and diagnosis lead to improved survival rates. However, most of OSCC cases are detected in advanced cancer. In this case, delayed detection may result in a high OSCC mortality rate ([@b5-mmr-17-02-2982]). In addition, OSCC has a high recurrence rate in many patients ([@b6-mmr-17-02-2982]). Therefore, the development of novel methods to predict the prognosis of OSCC is urgent.

Several previous studies have revealed that molecular-based classification may improve the prognosis of OSCC. For example, Belbin *et al* ([@b7-mmr-17-02-2982]) were able to distinguish two subgroups of OSCC using a set of molecular signatures that are distinct in the two different groups such as transforming growth factor-β. Another study identified crucial gene expressions in tumors and four subgroups of OSCC using cDNA microarrays ([@b8-mmr-17-02-2982]). Human papilloma virus (HPV) infection has a close relationship with OSCC, and the high risk of infection is associated with the high risk of developing OSCC ([@b9-mmr-17-02-2982]). In addition, the etiologies of HPV-positive and HPV-negative OSCC subtypes are different, and 347 differentially expressed genes have been identified in these two groups, such as thymidylate synthetase, stathmin 1 and cyclin D1 ([@b9-mmr-17-02-2982]). Notably, HPV-positive oral cancers have an improved response to treatment and better prognosis compared with HPV-negative OSCCs ([@b10-mmr-17-02-2982]). One previous study further predicted that HPV types 16 and 18 may be two independent risk factors for oral cancer ([@b11-mmr-17-02-2982]). A recently study used two expression data sets, a training data set and a validation data set to identify genes with distinct expressions between patients with HPV-negative OSCC and normal controls. Subsequently, a set of 131 gene signatures was selected, which was reduced to a total of 13 gene signatures that were identified as the best survival predictors for patients with HPV-negative OSCC ([@b12-mmr-17-02-2982]).

However, none of the aforementioned studies compared the precision of these classifications with the tumor-node-metastasis (TNM) stage. In addition, the patients used in a study by Lohavanichbutr *et al* were in different tumoral stages, and additional data is required ([@b12-mmr-17-02-2982]). Therefore, the present study reanalyzed their data set, GSE41613, and extracted only the data associated with patients with HPV-negative OSCC. The patients were subsequently classified based on the TNM stage; subsequently, signature genes were identified in the two groups, and patient samples were further classified based on these signature genes. Following this classification, two validation data sets, GSE42743 ([@b12-mmr-17-02-2982]) and GSE26549 ([@b13-mmr-17-02-2982]), were used to detect the precision of the signature-gene-based classification. In addition, survival analysis was performed in each classification. Through these comprehensive analyses, the present study aimed to identify several gene signatures that were able to distinguish patients with HPV-negative OSCC at different TNM stages.

Materials and methods
=====================

### Data resource and the pretreatments

Data set GSE41613 ([@b12-mmr-17-02-2982]) was obtained from the Gene Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/geo/>). This expression profile was based on the Affymetrix Human Genome U133 Plus 2.0 Array platform, and included 97 human samples from patients with HPV-negative OSCC, along with their clinical follow-up information. Among these samples, 30 patients succumbed to OSCC, 21 succumbed to other diseases and the remaining 46 patients survived, and these were classified in stages I to IV.

The data, which were already normalized, were downloaded and 76 of the OSCC-related samples were used in the present study; that is, the 30 patients that succumbed to OSCC and the 46 surviving patients. A set of 54,613 probe values was acquired, following the elimination of probes in empty carriers.

### Classification of different samples

Patients were classified based on TNM stage; those in stages I and II were placed in the low (L) stage, whereas those in stages III and IV were placed in the high (H) stage. Survival analysis was an important prognostic analysis and it was implemented according to the survival package in the R software (R 3.4.1; <https://www.r-project.org/>) ([@b14-mmr-17-02-2982]).

### Signature gene identification in L and H samples

To identify the optimal signature genes that were able to distinguish samples between the L and H groups, the disparity index s was calculated according to each gene expression, based on the formula: F~i~=(mean~iH~-mean~iL~)/(SD~iH~ + SD~iL~); where i represents a gene and F~i~ represents its corresponding disparity index in the different samples ([@b15-mmr-17-02-2982]). The significance of each gene to distinguish the different groups of samples was calculated using the permutation test by perm in R ([@b16-mmr-17-02-2982]). The iteration step k with an interval of 0.01 in 0--1 was used to identify the best threshold of Fi. The optimal signature genes were selected based on the criteria \|F\|\>k and P\<0.01. The selected genes were used to establish the classification model:
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Where i represents a gene, e~i~ represents its gene expression value, N represents selected gene numbers and PS~j~ is the score reflecting the classification of the sample j. Two classifications, positive and negative, were identified based on these scores. The overlap scale of the samples under these two classifications compared with that under the H and L classifications were calculated to identify the optimal signature genes under the classification threshold that had the best consistency.

### Fivefold cross validation

To detect the stability of using these signature genes to classify the samples, fivefold cross validation was implemented 10 times, and the overlap scale of the classifications under each cross validation with the classifications of H and L was calculated.

### Clinical prognostic analysis for samples classified based on signature genes

To determine the prognostic difference between the samples classified by signature genes, the samples were clustered into two groups based on the PSj scores calculated by the established model, and the survival package in R was used to analyze the prognostic difference of the two clusters ([@b14-mmr-17-02-2982]).

### Expression profile analysis of signature genes

Unsupervised hierarchical clustering was conducted for the signature genes, based on their expression values in different samples. Subsequently, the prognostic differences in different clusters were identified using the Kaplan-Meier package in R ([@b17-mmr-17-02-2982]).

### Enrichment analyses of signature genes

Function and pathway enrichment analyses of the signature genes were performed based on the Gene Ontology (GO; <http://www.geneontology.org>) and Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.jp/kegg/pathway.html>) databases, respectively, and the Database for Annotation, Visualization and Integration Discovery (DAVID; <http://david.abcc.Ncifcrf.gov>) online tool ([@b18-mmr-17-02-2982]). A threshold of P\<0.05 was used to indicate significant function and pathway categories.

### Multivariate survival analysis of signature genes

Signature genes were examined by multivariate survival analysis to determine their putative effects on prognosis as a whole. Receiver operating characteristic (ROC) curve was depicted using the SurvivalROC package in R ([@b19-mmr-17-02-2982]).

### Validation by individual gene data sets

To validate the reproducibility of the established model in classifying the OSCC samples to different prognosis groups, two independent gene expression profiles, GSE42743 ([@b12-mmr-17-02-2982]) and GSE26549 ([@b13-mmr-17-02-2982]), were downloaded from the GEO database, which were based on the Affymetrix Human Genome U133 Plus 2.0 Array platform and the Affymetrix Human Gene 1.0 ST Array \[transcript (gene) version\] platform, respectively. A total of 103 samples were in the GSE42743 data set, which also contained follow-up information of 23 patients succumbed to OSCC and 22 patients alive until the final follow-up time point. In this data set, raw data in the CEL format was obtained by ReadAffy in the affy package of R, and was normalized by robust multichip average ([@b20-mmr-17-02-2982],[@b21-mmr-17-02-2982]). The GSE26549 data set comprised 86 samples: 35 were recurrent patients and 51 were non-recurrent, and the normalized data in this profile was downloaded. Cox regression was used to analyze these data sets, and to compare prognostic and recurrent differences between different samples using the survival package in R ([@b14-mmr-17-02-2982]).

Results
=======

### Survival analysis of H and L samples

Samples were divided into two types, H and L, based on TNM stages. Survival analysis results indicated that there were significant differences between the two classifications, and patients in the L stage had a significantly higher survival probability compared with those in the H stage (P=2.00×10^−05^; [Fig. 1](#f1-mmr-17-02-2982){ref-type="fig"}).

### Threshold of signature genes in different samples

The gene set contained a total of 54,613 probes in the 76 GSE41613 tumor samples used. The overlap scale of the classifications obtained was compared using different F~i~ values in the classification model and the H and L classifications. As a result, the classification accuracy under different F~i~ values was not completely consistent: When the F~i~ was low and more gene sets were contained than others, the accuracy was \~0.86 ([Fig. 2A](#f2-mmr-17-02-2982){ref-type="fig"}); when F~i~ was 0.35--0.5, the accuracy was slightly improved and reached a maximum at F~i~=0.47. However, when the F~i~ was \>0.5, the accuracy exhibited a linear decline ([Fig. 2A](#f2-mmr-17-02-2982){ref-type="fig"}). Therefore, F~i~=0.47 was used as the cut-off value to classify the samples. Results from fivefold cross-validation analysis indicated that the accuracy was almost always \>80%, and the average value was 0.897 ([Fig. 2B](#f2-mmr-17-02-2982){ref-type="fig"}). This result confirmed the precise classification using gene sets with F~i~=0.47).

### Signature genes and gene expression profile analysis

Signature gene sets under the threshold of F~i~=0.47 were selected, and 24 genes were identified ([Table I](#tI-mmr-17-02-2982){ref-type="table"}). These genes were subsequently used to mark each sample, based on the classification model. Samples in H stage had a significantly higher score compared with those in L stage, and '0' was used as the boundary to divide the two samples ([Fig. 3A](#f3-mmr-17-02-2982){ref-type="fig"}). Survival analysis using 0 as the boundary indicated that there were significant prognostic differences between the two sample clusters (P=6.30×10^−07^; [Fig. 3B](#f3-mmr-17-02-2982){ref-type="fig"}). Notably, the difference was more significant than those determined in H and L classifications, which suggested that this score-based model was able to adjust the original model with H and L. Unsupervised hierarchical clustering analysis of gene expression profiles revealed that these signature genes could distinctly divide the samples into two classifications: Cluster1 and Cluster2 ([Fig. 3C](#f3-mmr-17-02-2982){ref-type="fig"}). Kaplan-Meier survival curve of these sample clusters also demonstrated significant differences (P=2.00×10^−05^; [Fig. 3D](#f3-mmr-17-02-2982){ref-type="fig"}). These data suggested that the samples could be distinguished by using gene expression clustering.

### Function enrichment of signature genes

As indicated in [Table II](#tII-mmr-17-02-2982){ref-type="table"}, the 24 signature genes were enriched in 1 KEGG pathway, ether lipid metabolism pathway \[P=0.0472; genes: 1-acylglycerol-3-phosphate O-acyltransferase 2 (AGPAT2) and phosphatidic acid phosphatase type 2B (PPAP2B)\], and 31 GO functional categories, including 1 cellular component, cell projection part \[P=0.0263; genes: protease, serine 12 (PRSS12), coiled-coil and C2 domain containing 2A (CC2D2A) and adenosine deaminase (ADA)\] and 30 biological processes (BPs), such as phagocytosis \[P=0.0016; genes: thrombospondin 1 (THBS1), solute carrier family 11 member 1 (SLC11A) and Jumonji domain containing 6 (JMJD6)\], regulation of dendritic cell antigen processing and presentation (P=0.0025; genes: THBS1 and SLC11A1), apoptotic cell clearance (P=0.0075; genes: THBS1 and JMJD6), T cell activation (P=0.0107; genes: ADA, SLC11A1 and JMJD6), lymphocyte activation during immune response (P=0.0224; genes: ADA, SLC11A1) and leukocyte activation during immune response (P=0.0443; genes: ADA and SLC11A1).

### Survival analysis of 24 signature genes

The 24 signature genes exhibited a clustering effect with an area under the ROC curve (AUC) of 0.97 ([Fig. 4A](#f4-mmr-17-02-2982){ref-type="fig"}), and a significant difference in survival was identified between the H and L classifications (P=2.48×10^−19^; [Fig. 4B](#f4-mmr-17-02-2982){ref-type="fig"}), which suggested that the 24 genes were able to effectively classify different samples and to predict the prognostic risk.

### Validation of the classification by individual data sets

The model containing 24 signature genes were demonstrated to be able to classify samples into two prognosis distinct groups in the GSE42743 data set (AUC=0.994) ([Fig. 5A](#f5-mmr-17-02-2982){ref-type="fig"}). The survival time between high and low risk samples was different significantly (P=4.55×10^−15^; [Fig. 5B](#f5-mmr-17-02-2982){ref-type="fig"}).

Similarly, the model classified samples into two recurrence risk groups in the GSE26549 data set (AUC=0.984; [Fig. 5C](#f5-mmr-17-02-2982){ref-type="fig"}). A Kaplan-Meier curve indicated a significant different recurrence risk between high and low risk samples (P=1.41×10^−14^; [Fig. 5D](#f5-mmr-17-02-2982){ref-type="fig"}).

Discussion
==========

OSCC has a poor prognosis and molecular-based classification provide improved the prognosis. In the present study, 24 signature genes, including *AGPAT2*, *PPAP2B*, *SLC11A1*, *JMJD6* and *ADA*, were identified that were able to classify the patients with HPV-negative OSCC into two different stages, H and L. They were significantly enriched in the ether lipid metabolism pathway and immune response- or apoptosis-related GO BPs.

The protein encoded by *AGPAT2* (1-AGPAT 2) is specific for lysophosphatidic acid (LPA) ([@b22-mmr-17-02-2982]). It is involved in the lipid metabolism, as it catalyzes LPA conversion into phosphatidic acid (PA), a crucial intermediate step in phospholipid biosynthesis ([@b23-mmr-17-02-2982]). 1-AGPAT 2 is an essential factor for adipogenesis; it serves a role in controlling adipogenesis by mediating the activation of phosphatidylinositol 3-kinase (PI3K)/Akt signaling ([@b24-mmr-17-02-2982]). Mutation of this gene may result in an adipogenic defects ([@b24-mmr-17-02-2982]). One previous study revealed that disruption of *AGPAT2* leads to severe congenital generalized lipodystrophy in humans ([@b25-mmr-17-02-2982]). *PPAP2B* is a phosphatidic acid phosphatase (PAP) family member that converts PA to diacylglycerol, and the PAP2B protein was reported to be involved in the regulation of intracellular lipid metabolism ([@b26-mmr-17-02-2982]).

Lipid metabolism has an important role in cancer progression. It has been proposed that increased lipid metabolic flux may serve as the substrate source for phospholipid synthesis in the rapid growth stage of cancer cells ([@b27-mmr-17-02-2982]). Notably, fatty acid synthase was demonstrated to be necessary during the proliferation of human OSCCs ([@b28-mmr-17-02-2982]). In addition, fatty-acid-binding protein 5 is upregulated in OSCC at the early stage, and this upregulated expression was reported to improve OSCC cell proliferation and invasiveness ([@b29-mmr-17-02-2982]). Results from the present study predicted *AGPAT2* and *PPAP2B* as two signature genes that could differentiate OSCC samples from different stages, and both of these genes were significantly enriched in the ether lipid metabolism pathway. These data suggested that the two genes may serve crucial roles in the progression of OSCC by regulating lipid metabolism, and may be used as therapeutic markers for early stage OSCC prognosis.

The immune system is known to serve crucial roles in the control of cancer development ([@b30-mmr-17-02-2982],[@b31-mmr-17-02-2982]). Inadequate host immune responses may account for the high incidence rates of cancer and poor prognosis ([@b32-mmr-17-02-2982]). Patients with OSCC in different pathological lymph node (pN) statuses exhibit different overall survival rates; patients with OSCC in pN3 (that is, extracapsular spread) have a lower overall survival compared with patients in other stages, which may be due to a relatively decreased host immune response ([@b32-mmr-17-02-2982]). A previous study using an immunoproteomics method identified several host immune response-related protein candidates in the serum of patients with OSCC, such as clusterin, haptoglobin and complement C3c ([@b33-mmr-17-02-2982]).

The multi-pass membrane protein SLC11A1, also known as natural resistance-associated macrophage protein 1 (NRAMP1), serves important role in host innate immune response against infections ([@b34-mmr-17-02-2982]). ADA functions in the process of A-to-I RNA editing to generate the inosine (I) from adenosine (A); the double-stranded RNA structure may then trigger innate immune responses ([@b35-mmr-17-02-2982]). Elevated *ADA* levels have been detected in a number of cancers, such as colorectal cancer and breast cancer ([@b36-mmr-17-02-2982],[@b37-mmr-17-02-2982]). In patients with OSCC, the expression levels of *ADA* are significantly increased compared with the healthy control patients ([@b38-mmr-17-02-2982]). Notably, this increased expression level was significantly associated with the histopathological grade ([@b38-mmr-17-02-2982]). The present results indicated that *SLC11A1* and *ADA* were two of the signature genes that were differentially expressed in the two stages of the classification model, and both were enriched in GO BPs, such as positive regulation of adaptive immune response and leukocyte activation during immune response, which suggested that they may function in the development of OSCC through the involvement of immune response-related processes. Based on these results, the present study speculated that *SLC11A1* and *ADA* may also be used as prognostic targets in different tumor stages of OSCC.

The protein encoded by *JMJD6* was previously considered to serve a role in the phagocytosis of apoptotic cells ([@b39-mmr-17-02-2982]). However, subsequent studies failed to confirm this function and, conversely, indicated that it translocates to the nucleus and serves as a histone arginine demethylase ([@b40-mmr-17-02-2982]), or it may be responsible for angiogenic sprouting ([@b41-mmr-17-02-2982]). Another study reported that *JMJD6* may improve cancer stem cell (CSC) phenotypes in OSCC cells ([@b42-mmr-17-02-2982]). In addition, increased *JMJD6* expression was previously demonstrated in CSC-enriched populations of OSCC cell lines, which may contribute to oral carcinogenesis and, therefore, it has been suggested as a potential biomarker of oral cancer ([@b43-mmr-17-02-2982]). In the present study, *JMJD6* was amongst the 24 signature genes able to classify patients with OSCC into different tumor stages. Notably, *JMJD6* was significantly enriched in the GO BP category apoptotic cell clearance, which indicated a potential role for JMJD6 in clearing apoptotic cells, at least in OSCC cells. Therefore, *JMJD6* may be considered another novel biomarkers for OSCC prognosis, relating to different tumor stages.

Although the accuracy of using these 24 signature genes to classify different tumor stages of OSCC was validated by other data sets and provided satisfactory results, there were several limitations to the present study: i) None of the identified gene expressions in OSCC, particularly in HPV-negative OSCC, were validated experimentally; and ii) the obtained OSCC sample data were classified into L and H stages, which may have caused deviations from the true TNM stages. Further studies using additional data sets are required to confirm the precision of our classification and the signature gene functions.

In conclusion, a novel 24-gene set was identified that was able to predict OSCC prognosis with high accuracy, which may have the benefit of aiding in the determination of an appropriate treatment program for patients with OSCC, in addition to the traditional evaluation index. *AGPAT2*, *PPAP2B*, *SLC11A1*, *ADA* and *JMJD6* may be biomarkers for OSCC prognosis; however, further experimental validation is required to confirm these predictions.

The study was supported by a grant from The General Program of Health Bureau of Shanghai (grant no. 20133124), and The 1255 project of Changhai Hospital of Second Military Medical University (grant no. CH125541800).

![Kaplan-Meier curve analysis indicated a significant difference in survival between H (n=41) and L (n=35) stages samples based on tumor-node-metastasis classification. P=2.00×10^−05^. H, high; L, low.](MMR-17-02-2982-g01){#f1-mmr-17-02-2982}

![Optimal threshold selection in the classification model. (A) Overlap scale of classifications using the model with the High and Low classifications. Gene sets with \|F~i~\|\>k were selected, and k from 0--1 was set with a step size of 0.01; F~i~=0.47 (vertical line) was used as the cut-off value to classify the samples. (B) 5-fold cross validation results for 10 iterations, which are indicated by the different colored lines. F~i~, disparity index; k, iteration step.](MMR-17-02-2982-g02){#f2-mmr-17-02-2982}

![Clustering analysis of signature gene expressions and corresponding survival analyses. (A) Signature genes were used to mark samples in H and L classifications under the score-classification model. (B) Kaplan-Meier curve indicating a significant difference in survival between Cluster 1 and Cluster2 classified with the boundary of '0'. (C) Heat map of signature gene expressions in two cluster samples. (D) Kaplan-Meier curve indicating a significant difference in survival between Cluster1 and Cluster2 that were identified by expression profiling of the signature genes. H, high; L, low.](MMR-17-02-2982-g03){#f3-mmr-17-02-2982}

![Multivariate survival analysis of 24 signature genes. (A) ROC curve; AUC=0.97. (B) Kaplan-Meier curve indicating a significant difference in survival between high-risk and low-risk samples identified by the multivariate prognosis of 24 genes; P=2.48×10^−19^. AUC, area under the ROC curve; ROC, receiver operating characteristic.](MMR-17-02-2982-g04){#f4-mmr-17-02-2982}

![Validation of survival analysis using two additional data sets. (A) ROC curve of the classification in the GSE42743 data set; AUC=0.994. (B) Kaplan-Meier curve indicating a significant difference in survival between high and low risk samples in GSE42743; P=4.55×10^−15^. (C) ROC curve of the recurrent classification in the GSE26549 data set; AUC=0.984. (D) Kaplan-Meier curve indicating a significant difference between high and low risk samples in GSE26549; P=1.41×10^−14^. AUC, area under the ROC curve; ROC, receiver operating characteristic.](MMR-17-02-2982-g05){#f5-mmr-17-02-2982}

###### 

List of 24 signature genes.

  Gene symbol   Gene name
  ------------- ------------------------------------------------------------------------------------------------------
  ADA           Adenosine deaminase
  CC2D2A        Coiled-coil and C2-domain containing 2A
  C9ORF102      Chromosome 9 open reading frame 102
  PRSS12        Protease, serine 12 (also known as neurotrypsin and motopsin)
  TNXB          Tenascin XB
  SLC11A1       Solute carrier family 11 member 1 (alsoknown as natural resistance-associatedmacrophage protein 1)
  GAPVD1        GTPase activating protein and VPS9domains 1
  THBS1         Thrombospondin 1
  C19ORF53      Chromosome 19 open reading frame 53
  IGSF10        Immunoglobulin superfamily, member 10
  PLGLB2        Plasminogen-like B2
  ROD1          ROD1 regulator of differentiation 1 (alsoknown as polypyrimidine tract-bindingprotein 3)
  AGPAT2        1-acylglycerol-3-phosphate O-acyltransferase2 (also known as lysophosphatidic acidacyltransferase β)
  SESN3         Sestrin 3
  CSNK1G1       Casein kinase 1 γ1
  HMGN3         High-mobility group nucleosomal-bindingdomain 3
  SLC2A3        Solute carrier family 2 member 3
  FAM161A       Family with sequence similarity 161member A
  DDX31         DEAD-box helicase 31
  JMJD6         Jumonji-domain containing 6 (also knownas arginine demethylase and lysine hydrolase)
  PPAP2B        Phosphatidic acid phosphatase type 2B (alsoknown as phospholipid phosphatase 3)
  YEATS2        YEATS-domain containing 2
  SERTAD4       SERTA-domain containing 4
  NAPEPLD       N-acyl phosphatidylethanolaminephospholipase D

###### 

GO function term and KEGG pathway enrichment analysis of 24 signature genes.

  A, GOTERM_BP                                                                                                                                                   P-value       Genes
  -------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- --------------------------------
  GO:0006909\~phagocytosis                                                                                                                                       0.0016        THBS1, SLC11A1 and JMJD6
  GO:0006897\~endocytosis                                                                                                                                        0.0024        THBS1, SLC11A1, and JMJD6
  GO:0010324\~membrane invagination                                                                                                                              0.0024        THBS1, SLC11A1, and JMJD6
  GO:0002604\~regulation of dendritic cell antigen processing and presentation                                                                                   0.0025        THBS1 and SLC11A1
  GO:0002577\~regulation of antigen processing and presentation                                                                                                  0.0025        THBS1 and SLC11A1
  GO:0051240\~positive regulation of multicellular organismal process                                                                                            0.0033        THBS1, AGPAT2, ADA and SLC11A1
  GO:0001819\~positive regulation of cytokine production                                                                                                         0.0056        THBS1, AGPAT2 and SLC11A1
  GO:0043277\~apoptotic cell clearance                                                                                                                           0.0075        THBS1 and JMJD6
  GO:0042110\~T cell activation                                                                                                                                  0.0107        ADA, SLC11A1 and JMJD6
  GO:0016044\~membrane organization                                                                                                                              0.0112        THBS1, SLC11A1, and JMJD6
  GO:0051241\~negative regulation of multicellular organismal process                                                                                            0.0176        THBS1, ADA and SLC11A1
  GO:0042116\~macrophage activation                                                                                                                              0.0187        SLC11A1 and JMJD6
  GO:0001817\~regulation of cytokine production                                                                                                                  0.0212        THBS1, AGPAT2 and SLC11A1
  GO:0002285\~lymphocyte activation during immune response                                                                                                       0.0224        ADA and SLC11A1
  GO:0006644\~phospholipid metabolic process                                                                                                                     0.0232        AGPAT2, PPAP2B and NAPEPLD
  GO:0002685\~regulation of leukocyte migration                                                                                                                  0.0249        THBS1 and ADA
  GO:0046649\~lymphocyte activation                                                                                                                              0.0253        ADA, SLC11A1 and JMJD6
  GO:0019637\~organophosphate metabolic process                                                                                                                  0.0256        AGPAT2, PPAP2B and NAPEPLD
  GO:0016192\~vesicle-mediated transport                                                                                                                         0.0335        THBS1, SLC11A1, and JMJD6
  GO:0048584\~positive regulation of response to stimulus                                                                                                        0.0347        THBS1, ADA and SLC11A1
  GO:0002684\~positive regulation of immune system process                                                                                                       0.0352        THBS1, ADA and SLC11A1
  GO:0045321\~leukocyte activation                                                                                                                               0.0363        ADA, SLC11A1 and JMJD6
  GO:0002824\~positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains   0.0371        ADA and SLC11A1
  GO:0001568\~blood vessel development                                                                                                                           0.0372        THBS1, PPAP2B and JMJD6
  GO:0002821\~positive regulation of adaptive immune response                                                                                                    0.0383        ADA and SLC11A1
  GO:0001944\~vasculature development                                                                                                                            0.0388        THBS1, PPAP2B and JMJD6
  GO:0002366\~leukocyte activation during immune response                                                                                                        0.0443        ADA and SLC11A1
  GO:0002263\~cell activation during immune response                                                                                                             0.0443        ADA and SLC11A1
  GO:0001818\~negative regulation of cytokine production                                                                                                         0.0467        THBS1 and SLC11A1
  GO:0001775\~cell activation                                                                                                                                    0.0495        ADA, SLC11A1 and JMJD6
                                                                                                                                                                               
  **B, GOTERM_CC**                                                                                                                                               **P-value**   **Genes**
                                                                                                                                                                               
  GO:0044463\~cell projection part                                                                                                                               0.0263        PRSS12, CC2D2A and ADA
                                                                                                                                                                               
  **C, KEGG_PATHWAY**                                                                                                                                            **P-value**   **Genes**
                                                                                                                                                                               
  hsa00565: Ether lipid metabolism                                                                                                                               0.0472        AGPAT2 and PPAP2B

ADA, adenosine deaminase; AGPAT2, 1-acylglycerol-3-phosphate O-acyltransferase 2; BP, biological process; CC, cellular component; CC2D2A, coiled-coil and C2-domain containing 2A; GO, gene ontology; JMJD6, Jumonji-domain containing 6; KEGG, Kyoto Encyclopedia of Genes and Genomes; NAPEPLD, N-acyl phosphatidylethanolamine phospholipase D; PPAP2B, phosphatidic acid phosphatase type 2B; PRSS12, protease, serine 12; SLC11A1, solute carrier family 11 member 1; THBX, thrombospondin 1.

[^1]: Contributed equally
